SYDNEY, Sept. 13, 2019 /PRNewswire/KOREA IT TIMES -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards.
The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and were presented by New Zealand Prime Minister Jacinda Arden at a ceremony in Auckland on September 12.
Kazia was recognised for being an innovative, product-focused and agile company and the award also reflected its significant progress in the clinical testing of its lead candidate, GDC-0084, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults, as well as other forms of brain cancer.
The Awards are run by the Australia New Zealand Leadership Forum (ANZLF) which brings senior business and government leaders together to help Australia and New Zealand prosper in the global economy.
Kazia CEO, Dr James Garner said, "We are thrilled to have been named as a winner in the Awards and to have been recognised not only for our diverse team and growth culture, but also for our innovative work in the clinical testing of drugs such as our lead candidate, GDC-0084, which is being developed to treat a range of brain cancers including glioblastoma as well as the aggressive childhood brain cancer, diffuse intrinsic pontine glioma (DIPG)."
On the DIPG clinical program front, Kazia also announced that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of GDC-0084 in DIPG.
The study, which has to date dosed thirteen patients with GDC-0084, has determined a maximum tolerated dose (MTD) of 27 mg/m2 for paediatric use. In addition, the safety profile of the drug in children appears to be broadly similar to that in adults.
St Jude's will now advance into the second stage of the study, which is designed to explore signals of efficacy in this disease.
Dr Garner said, "DIPG is a devastating illness with a poor prognosis and a paucity of effective treatments. It has been a privilege to support the St Jude team on this incredibly important project. The study has recruited well ahead of our expectations, and we are delighted to have the first part successfully completed. Toxicity can be a significant challenge in the treatment of childhood cancer, so it is very encouraging that GDC-0084 appears to have an acceptable tolerability profile. We are excited to see further data in due course."
For more information, please see the full ASX Announcement: https://www.asx.com.au/asxpdf/20190912/pdf/448gjpmtl71wf7.pdf